Anti-CA19-9 antibody [121SLE]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

CA19-9 also known as carbohydrate antigen 19-9 or sialyl-Lewis A is a glycoprotein with a molecular mass of around 210 kDa. This antigen is mainly expressed on the surface of epithelial cells in the pancreas liver gallbladder and stomach. It serves as a well-recognized tumor marker for cancers associated with these organs. CA19-9 can be detected using techniques like immunohistochemistry (IHC) aiding in diagnostic and research applications.

Biological function summary

CA19-9 plays a role in cell-cell communication and adhesion contributing to the behavior of cancer cells regarding metastasis and invasion. It is part of a broader complex involving glycoproteins which is important in cell surface recognition and signaling events. In normal cellular roles functions are less prominent but the alterations in cancerous cells highlight its biological significance in oncogenesis.

Pathways

CA19-9 interacts with several signal transduction pathways that influence cellular processes like proliferation and migration. Notably it is involved in the EGF receptor pathway affecting cellular growth and survival mechanisms. It relates to glycosylation pathways which together with other proteins such as MUC1 modify cellular membranes in malignant tissues influencing tumor progression and evasion from immune detection.

Associated diseases and disorders

CA19-9 frequently connects with pancreatic cancer and cholangiocarcinoma serving as a biomarker for diagnosis and monitoring disease progression. Its levels often increase in response to malignancies in these tissues. Studies suggest its interaction with proteins like CEACAM6 might enhance tumor invasiveness and metastasis. Identifying elevated CA19-9 can guide clinical decisions and therapeutic strategies in affected individuals.